EUDA Health Holdings (NASDAQ:EUDA) has unveiled a nationwide stem cell extraction, cryostorage, and clinical delivery platform in China, marking a massive expansion of its footprint in the regional longevity and regenerative medicine sector.
Announced on Dec. 30, the platform is built through strategic partnerships with Shenzhen Inno Immune Co. and Wuhan Kaien Hospital.
The infrastructure is designed to provide a "closed-loop" ecosystem that connects decentralized extraction clinics across China to centralized high-tech processing and storage hubs.
The initial infrastructure includes a primary cell processing hub in Shenzhen with an initial capacity of approximately 50,000 patient units.
This will be followed by a significantly larger facility at Wuhan Kaien Hospital, which is planned to support up to 200,000 patient units.
The Wuhan site will serve as the flagship for EUDA's Central China operations, integrating both inpatient and outpatient services for longevity and chronic disease management.
To ensure the integrity of the samples during transit, EUDA has integrated professional cold-chain logistics to move cellular materials between the network of partner extraction clinics and the central hubs.